Navigation auf uzh.ch
Navigation auf uzh.ch
Dear colleagues,
The new drugs for the treatment of Hepatitis C Virus infection will bring new chances but also challenges for treatment and diagnostics. To obtain an update on evolving new drugs against HCV, their resistance patterns and the ensuing consequences for treatment and diagnostics we will hold a Mini-Symposium on Dec 8, 2011 at the University Hospital Zurich.The program and further details on the symposium can be downloaded from our website http://www.virology.uzh.ch/newsd_en.html.
We hope you find this topic interesting and look forward to see you in December.
Sincerely,
Alexandra Trkola
On behalf of the program committee
| Alexandra Trkola | Institute of Medical Virology, University of Zurich |
| Huldrych Günthard | Division of Infectious Diseases, University Hospital Zurich |
| Jürg Böni | Institute of Medical Virology, University of Zurich |
| Andri Rauch | Division of Infectious Diseases, Inselspital Bern |
| Beat Müllhaupt | Division of Gastroenterology and Hepatology, University Hospital Zurich |
December 8, 2011
University Hospital Zurich, Rämistrasse 100, 8091 Zürich
Hörsaal West, 14h-19h
| Program: | |
| Admission: | There is no admission fee. |
| Registration: | Registration is required. Please send an email to wiget.monika@virology.uzh.ch to register for the symposium. |
| Lodging and travel: | We kindly ask participants to organize travel and accommodation individually. |
| Credits: | This symposium is recognized with 4 CME credits by the FAMH, Microbiology, the Swiss Society of Gastroenterology and the Swiss Society of Infectious Diseases. |
Speakers
| Stefan Zeuzem | Johann Wolfgang Goethe-Universität, Frankfurt | New HCV therapies |
| David Wyles | University of California, San Diego | New drugs and resistance |
| Karin Metzner | University Hospital Zurich | Resistance testing: Lessons from HIV, Options for HCV |
| Stephane Chevaliez | Université Paris-Est Créteil | How to use virological tools for the optimal management of chronic hepatitis C |
| Markus Heim | Universität Basel | The future of interferon therapy |
| Roche Diagnostics (Schweiz) AG Roche Pharma (Schweiz) AG Merck Sharp&Dohme-Cibret AG Janssen-Cilag AG |
| And a generous contribution by Abbott AG |
